Pages that link to "Q33645191"
Jump to navigation
Jump to search
The following pages link to A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer (Q33645191):
Displaying 10 items.
- Neoadjuvant nab-paclitaxel in the treatment of breast cancer (Q26748822) (← links)
- Clinical Translation of Nanomedicine. (Q30355939) (← links)
- A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases (Q33405667) (← links)
- Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval (Q35128729) (← links)
- Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review (Q35303471) (← links)
- Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis (Q37725620) (← links)
- Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. (Q38613025) (← links)
- Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. (Q38658509) (← links)
- Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer (Q39243591) (← links)
- Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. (Q53008476) (← links)